

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Boehringer Ingelheim Pharma GmbH & Co. KG	12/20/2012
RECEIVING PARTY DATA	
Name:	Onclave Therapeutics
Street Address:	Treasury Building, Lower Grand Canal Street
City:	Dublin 2
State/Country:	IRELAND
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13660957
CORRESPONDENCE DATA	
Fax Number:	7039182286
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	7033942253
Email:	jmeigs@wcsr.com
Correspondent Name:	WOMBLE CARLYLE SANDRIDGE & RICE, LLP
Address Line 1:	P.O. BOX 7037
Address Line 4:	ATLANTA, GEORGIA 30357-0037
ATTORNEY DOCKET NUMBER:	E090 1040US.1
NAME OF SUBMITTER:	Julie Broadus Meigs, Ph.D.
Total Attachments: 4 source=E090_1040US_1_ASSIGNMENT_Boehringer_to_ONCLAVE#page1.tif source=E090_1040US_1_ASSIGNMENT_Boehringer_to_ONCLAVE#page2.tif source=E090_1040US_1_ASSIGNMENT_Boehringer_to_ONCLAVE#page3.tif source=E090_1040US_1_ASSIGNMENT_Boehringer_to_ONCLAVE#page4.tif	

CH \$40.00 13660957

## ASSIGNMENT OF PATENT APPLICATION

THIS ASSIGNMENT, by **Boehringer Ingelheim Pharma GmbH & Co. KG**, a corporation having its registered office at Binger Strasse 173, 55216 Ingelheim am Rhein, Germany (hereinafter referred to as "Assignors"), witnesseseth:

WHEREAS, Assignor is the owner of an undivided right, title, and interest in and to the invention set forth as follows:

Title of Invention: **ANTIBODY FORMULATIONS AND METHODS**

as set forth in U.S. Patent Application No. 13/660,957, filed 25 October 2012, which claims priority to U.S. Provisional Application No. 61/551,406, filed 25 October 2011;

WHEREAS, **ONCLAVE THERAPEUTICS** (formerly known as Elan Science Six Limited), a private limited company incorporated under the laws of Ireland, and having its registered office at **Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland** (hereinafter referred to as "Assignee"), pursuant to a Master Process Development and Clinical Supply Agreement, effective June 23, 2010 (hereinafter referred to as "the MPDCSA") between Elan Pharma International Limited, Neotope Biosciences Limited (predecessor in interest to Assignee), and Assignor, has acquired all of Assignor's right, title and interest in and to said invention, the right to file applications on said invention, and the right, title and interest in and to any applications, including provisional applications, on said invention for Letters Patent of the United States or other countries, and any applications claiming priority to said applications, and in and to any Letters Patent or Patents of any country, to be obtained therefore and thereon;

NOW, THEREFORE, pursuant to the MPDCSA, for good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over unto Assignee, and Assignee's successors, legal representatives, and assigns, all of Assignor's right, title, and interest in and to the above-mentioned invention and application, the right to file applications on said invention, and the right, title and interest in and to any such applications, including provisional applications, and any applications claiming priority from said applications for Letters Patent of the United States or other countries (including patent, utility model, and industrial designs), and in and to any and all Letters Patent or Patents of the United States of America and all foreign countries that have been or may be granted therefore and thereon and in and to any and all divisions, renewals, substitutions, conversions, continuations, and continuations-in-part of said applications, and reissues, prolongations and extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignors had their sale and assignment not been made;

AND Assignors hereby covenant that Assignor has the full right to convey the interest assigned by this Assignment, and Assignors has not executed and will not execute any agreement in conflict with this Assignment,

AND for the same consideration, Assignors hereby covenant and agree to and with Assignee, its successors, legal representatives, and assigns, that the Assignors shall, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, advises that any proceeding in connection with said invention or said applications for Letters Patent or Patents, or any proceeding in connection with Letters Patent or Patents for said inventions in any country, including interference proceedings, is lawful and desirable, or that any application claiming priority to said application, division, continuation, or continuation-in-part, substitution, or conversion of any applications for Letters Patent or Patents, or any reissue, prolongation, or extension of any Letters Patent or Patents to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said inventions, without charge to Assignee, its successors, legal representatives, and assigns, but at the cost and expense of Assignee, its successors, legal representatives, and assigns;

AND the undersigned hereby grant(s) an authorized representative of Assignee the power to insert in this Assignment the application number and filing date and further identification that may be necessary or desirable to comply with the rules for recordation of this Assignment.

IN TESTIMONY WHEREOF, Assignor has signed its names on the date indicated.


Date:

Boehringer Ingelheim Pharma GmbH & Co. KG  
ppa.



Dr. Elke SIMON  
Authorized Signatory

ppa.



Dr. Volker MAHLBACHER  
Authorized Signatory


EXECUTE IN THE PRESENCE OF A NOTARY



## Authentication of Signature

I hereby certify, that the signature under the document is the true signature, subscribed in my presence, of

1. Frau Dr. Elke Simon,  
geboren am 09.06.1961,  
wohnhaft in 65779 Kelkheim, Hornauer Straße 98,  
  
- ausgewiesen durch Personalausweis -
2. Herrn Dr. Volker Mahlbacher,  
geboren am 28.02.1962,  
wohnhaft in 88400 Biberach, Rissegger Strasse 66,  
  
- persönlich bekannt -



Biberach an der Riss, the 20.12.2012  
Notariat Biberach an der Riss I

Groß  
Notary

§§ KostO	Gegenstand	Geschäftswert	Betrag
§§ 45 I, 141, 32 KostO	Unterschriftsbeglaubigung	50.000,00 €	33,00 €
§§ 58 I, 141, 32 KostO	Auswärtsgebühr	50.000,00 €	30,00 €
	Umsatzsteuer 19,00% aus	63,00 €	11,97 €
Summe:			74,97 €
Rechnungs-Nr.	108146		

